Curis Inc. Faces Delisting Concerns

Ticker: CRIS · Form: 8-K · Filed: Oct 24, 2025 · CIK: 1108205

Curis INC 8-K Filing Summary
FieldDetail
CompanyCuris INC (CRIS)
Form Type8-K
Filed DateOct 24, 2025
Risk Levelhigh
Pages2
Reading Time3 min
Key Dollar Amounts$0.01, $35,000,000
Sentimentbearish

Sentiment: bearish

Topics: delisting, listing-standards, regulatory-filing

TL;DR

Curis is on the chopping block for delisting - big trouble ahead.

AI Summary

Curis, Inc. filed an 8-K on October 24, 2025, to report a notice of delisting or failure to satisfy a continued listing rule or standard. The company, incorporated in Delaware, is based in Lexington, MA, and operates in the biological products sector.

Why It Matters

This filing indicates potential issues with Curis, Inc.'s ability to remain listed on its stock exchange, which could significantly impact its stock price and investor confidence.

Risk Assessment

Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's continued operation and investor value.

Key Numbers

Key Players & Entities

FAQ

What specific listing rule or standard has Curis, Inc. failed to satisfy?

The filing does not specify the exact rule or standard that Curis, Inc. has failed to satisfy, only that a notice has been received.

What is the earliest date of the event reported in this 8-K?

The earliest event reported is dated October 20, 2025.

What is the primary business of Curis, Inc. according to the filing?

Curis, Inc. is in the business of Biological Products (No Diagnostic Substances).

Where are Curis, Inc.'s principal executive offices located?

The principal executive offices are located at 128 Spring Street, Building C - Suite 500, Lexington, MA 02421.

What is the filing date of this 8-K report?

This 8-K report was filed on October 24, 2025.

Filing Stats: 632 words · 3 min read · ~2 pages · Grade level 13.7 · Accepted 2025-10-24 16:02:45

Key Financial Figures

Filing Documents

01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, on August 21, 2025, Curis, Inc. (the "Company") received notice from the Listing Qualifications Department (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") stating that, because the Company has not regained compliance with Nasdaq Listing Rule 5550(b)(2) (the "MVLS Requirement") which requires the market value of the Company's listed securities to be at least $35,000,000, its securities would be delisted from The Nasdaq Capital Market unless the Company timely appeals the Staff's delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the "Panel") by August 28, 2025. The Company timely requested a hearing before the Panel, which request stayed any further suspension or delisting action by the Staff, pending the ultimate conclusion of the hearing process. On October 20, 2025, the Company received written notice from Nasdaq indicating that the Panel has granted the Company an exception until November 14, 2025 ("Exception Period") to regain compliance with the MVLS Requirement. During the Exception Period, the Company is required to provide prompt notification of any significant events that occur during this period that may affect the Company's compliance with Nasdaq requirements including any event that may call into question the Company's ability to meet the terms of the exception granted. The Panel reserves the right to reconsider the terms of this exception based on any event, condition or circumstance that exists or develops that would, in the opinion of the Panel, make continued listing of the Company's securities on Nasdaq inadvisable or unwarranted. There can be no assurance that the Company will ultimately regain compliance and remain listed on Nasdaq. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing